Patents Assigned to Boston Medical Center Corporation
  • Patent number: 12018058
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: June 25, 2024
    Assignee: Boston Medical Center Corporation
    Inventors: Steven C. Borkan, Zhiyong Wang
  • Patent number: 11970524
    Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: April 30, 2024
    Assignees: PFIZER INC., BOSTON MEDICAL CENTER CORPORATION
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
  • Publication number: 20240132853
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Application
    Filed: August 25, 2023
    Publication date: April 25, 2024
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo MOSTOSLAVSKY, Dar HEINZE
  • Patent number: 11883246
    Abstract: The inventions provided herein relate to tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: January 30, 2024
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Mark W. Grinstaff, Boris Nicolas Bloch, Jonah Kaplan
  • Publication number: 20230340418
    Abstract: The present application discloses compositions and methods for use of nucleoside modified mRNA that encode for at least one liver regenerative factor. The present invention also relates to compositions and methods for use of nucleoside modified mRNA complexed to nanoparticles. The disclosed compositions and methods are useful for treating acute liver diseases, chronic liver diseases, and/or acetaminophen (acetyl-para-aminophenol, APAP) overdose.
    Type: Application
    Filed: November 8, 2022
    Publication date: October 26, 2023
    Applicants: BOSTON MEDICAL CENTER CORPORATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Valerie Gouon-Evans, Drew Weissman, Norbert Pardi
  • Patent number: 11788065
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: October 17, 2023
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo Mostoslavsky, Dar Heinze
  • Patent number: 11464844
    Abstract: Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: October 11, 2022
    Assignee: Boston Medical Center Corporation
    Inventor: Richard N. Goldstein
  • Patent number: 11467158
    Abstract: The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CPT analogues such as topotecan and irinotecan and derivatives thereof. More specifically, the present invention related to methods, machines, computer systems, computable readable media and kits which can be used to determine a mutation in the BRCA1 gene, e.g.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 11, 2022
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventor: Ajit Bharti
  • Patent number: 11375918
    Abstract: Methods of characterizing the brain of a subject, comprising: (a) performing a multispectral multislice magnetic resonance scan on the brain of a subject, (b) storing image data indicative of a plurality of magnetic resonance weightings of each of a plurality of slices of the brain of the subject to provide directly acquired images, (c) processing the directly acquired images to generate a plurality of quantitative maps of the brain indicative of a plurality of qMRI parameters of the subject, (d) constructing a plurality of magnetic resonance images indicative of white matter structure from the quantitative maps, and (e) generating a spatial entropy map of the brain of the subject from the plurality of magnetic resonance images; and/or generating a myelin water map of the brain of the subject from the plurality of magnetic resonance images.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: July 5, 2022
    Assignees: Boston Medical Center Corporation, Trustees of Boston University
    Inventors: Hernan Jara, Ryan McNaughton
  • Patent number: 11365253
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 21, 2022
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Eric M. Bennett, Nathan Higginson-Scott, Huilan Gao, Zong Sean Juo, Stefano V. Gulla, Christine Huard, Sreekumar R. Kodangattil, Jian Li, Weining Lu, Xueping Fan, David J. Salant
  • Patent number: 11360102
    Abstract: Disclosed are biomarkers for Parkinson's disease (PD), including idiopathic PD (idPD). The present invention relates generally to assays, kits, compositions, solid supports and methods that measure a decrease in the expression or function of PLA2g6(L) variant of PLA2g6 (PARK 14) gene in a sample from the subject, including non-neuronal cells as a biomarker for preclinical (prodromal) or early stage Parkinson's disease (PD) and idiopathic PD (idPD), as well as assays, kits, compositions and methods that can detect the functional consequences of decreased expression of PLA2g6(L), including decreased store operated Ca2+ entry (SOCE), deficit of Ca2+ in endoplasmic reticulum stores, and autophagic dysfunction in the cells obtained from the subjects in preclinical (prodromal) and early stage PD diagnosis and for monitoring Parkinson's Disease progression.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: June 14, 2022
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventor: Victoria Bolotina
  • Patent number: 11337586
    Abstract: Disclosed herein is an aspiration assembly for attaching to an endoscope. The aspiration assembly comprises an extendable suction tube for aspirating an object (e.g., smoke, blood, blood clot, bone debris, or tissue debris) at or near a surgical site during an endoscopic surgery. The aspiration assembly can further comprise an irrigation tube for directing a fluid to the surgical site for cleaning the endoscope lens. By integrating an extendable suction tube with the endoscope, the technology described herein obviate the need for instrument switching and/or multiple surgeons during the surgery.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 24, 2022
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION, FRAUNHOFER USA, INC.
    Inventors: Anand Devaiah, Andre Sharon, Alexis Sauer-Budge, Holger Wirz, Yuzhang Yang, Stephanus Johannes Marcellis Van Der Kemp, Daniel Echeverria
  • Patent number: 11324799
    Abstract: The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 10, 2022
    Assignees: ZEALAND PHARMA A/S, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Bjarne Due Larsen, Ulrik Mouritzen, Dongjoon Kim, Sayon Roy
  • Publication number: 20210403521
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 30, 2021
    Applicant: Boston Medical Center Corporation
    Inventors: Steven C. BORKAN, Zhiyong WANG
  • Patent number: 11136363
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: October 5, 2021
    Assignee: Boston Medical Center Corporation
    Inventors: Steven C. Borkan, Zhiyong Wang
  • Patent number: 11124769
    Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: September 21, 2021
    Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITY
    Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
  • Patent number: 11122784
    Abstract: This application provides a novel mouse model (PLA2g6 KOEx2) in which genetic deletion of the N terminus of PLA2g6 results in a loss of dopaminergic (DA) neurons in substantia nigra (SN), and development of PD-like motor deficits that can be significantly improved by L-DOPA. Based in part on experimental results demonstrated with this model, this disclosure provides genetically modified animals and genetically modified animal cells that comprise a mutant allele of PLA2g6 and in which store-operated Ca2+ entry (SOCE) is impaired and ER Ca2+ stores are depleted. This disclosure also provides methods of screening a compound for an effect on the SOCE pathway and/or ER Ca2+ by administering the compound to such a genetically modified animal or genetically modified animal cell.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: September 21, 2021
    Assignee: Boston Medical Center Corporation
    Inventor: Victoria Bolotina
  • Publication number: 20210207100
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 8, 2021
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo MOSTOSLAVSKY, Dar HEINZE
  • Publication number: 20210121263
    Abstract: The inventions provided herein relate to tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 29, 2021
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Mark W. GRINSTAFF, Boris Nicolas BLOCH, Jonah KAPLAN
  • Patent number: 10906955
    Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 2, 2021
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant